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Abstract: Nuclear factor erythroid-2 related factor-2 (Nrf2) is a transcription factor, widely considered the master 
regulator of the antioxidant response. Under normal condition, its inhibitor, the Kelch-like ECH-associated protein 1 
(Keap1), binds Nrf2, causing its cytoplasmatic retention and mediating Nrf2 ubiquitination followed by proteasomal 
degradation; under oxidative stress, Nrf2 dissociates from Keap1, translocates into the nucleus, and induces the 
expression of genes bearing Antioxidant Responsive Element (ARE) in their promoters, such as phase II detoxifying 
enzymes and antioxidant genes. In these years several studies confirmed that Nrf2 has a cancer-protective activity via 
its cytoprotective functions; however, growing body of evidence showed that it is frequently activated in many resistant 
tumors, as an adaptative response to the increased oxidative stress. This activation makes cancer cells more resistant to 
drug treatments. Thus, its inhibition could sensitize tumor cells to pro-oxidant therapies, suggesting that the Nrf2 
inhibition, through chemical inhibitors or RNA interference strategies, is a promising tool in cancer therapy. 
As observed in many cancers, Nrf2 plays a role in the progression of brain tumors, such as astrocytomas, multiforme 
glioblastomas, gliosarcomas, medulloblastomas, oligodendroglial and ependymal tumors. However, most of the research 
focusing on the mechanisms in the regulation of Nrf2, as well as on its potential value in the cancer treatment, have been 
carried out in adult glioblastomas. Thus, little is known about the role of Nrf2 in most of the common childhood brain 
tumors. Here, we summarize and discuss findings on Nrf2 in common pediatric CNS tumors, as well as the clinical 
perspectives in using Nrf2 inhibitors for cancer CNS treatment. 
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1. NRF2: THE MASTER REGULATOR OF 
ANTIOXIDANT RESPONSE 
Nuclear factor erythroid-2 related factor-2 (Nrf2) is a 
Cap’n’collar basic leucine zipper transcription factor, 
widely considered the master regulator of the 
antioxidant response [1] Nrf2 acts by binding and 
positively regulating the expression of genes bearing 
Antioxidant Responsive Element (ARE) in their 
promoter. The Nrf2-regulated transcriptional program 
essentially controls the genes involved in the redox 
homeostasis, xenobiotics detoxification and multidrug- 
resistance [2]. Although Nrf2 has been found 
constitutively expressed in various tissues and cell 
lines [3], its activity is strictly controlled by posttrans-
lational mechanisms. In particular Kelch-like ECH-
associated protein 1 (Keap1) binds Nrf2, causing its 
cytoplasmatic retention and mediating Nrf2 ubiquitina-
tion followed by proteasomal degradation [4]. Keap1 is 
a cysteine-rich and redox-sensitive protein containing 
five functional domains, which include an N-terminal 
region (NTR), a broad-complex, tramtrack, bric a′ brac 
(BTB) homodimerization domain, a cysteine rich 
intervening region (IVR), a kelch/double glycine repeat 
(DGR) domain (harboring six Kelch repeats), and a C-
terminal region (CTR) [5]. The IVR domain contains 
highly reactive cysteine residues, such as Cys273, 
Cys288, and Cys297, which are easily oxidized and are 
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thus responsible for sensing oxidative stress [6]. Under 
oxidative stress, these highly reactive cysteine residues 
in Keap1 are oxidized, and Keap1 releases Nrf2 which 
translocates in the nucleus, where it heterodimerizes 
with the small Musculo Aponeurotic Fibrosarcoma 
protein (sMAF), and binds to ARE, inducing the 
transcription of a battery of cytoprotective proteins [7] 
(Figure 1). These include several Phase II detoxify-
cation enzymes, such as glutathione-S transferases 
(GSTs), NADPH quinine oxidoreductase (NQO1), 
glutathione peroxidases (GPx), catalase, superoxide 
dismutases (SODs), epoxide hydrolase, heme 
oxygenase (HO1), UDP-glucuronosyl transferases 
(UGTs), and gamma-glutamylcysteine synthetase 
(GCL), as well as many antioxidant genes such as the 
Glutamate-cysteine ligase, catalytic subunit (GCLC), 
glutaredoxin 1 (GLRX), glutathione reductase (GRS1), 
and peroxiredoxins 1 and 6 (PRDX1-6) [8-9]. Nrf2 
induces the expression of several enzymes involved in 
the synthesis of glutathione (GSH), the most important 
low-molecular weight antioxidant synthesized in cells 
[10]. The detoxification and the antioxidant enzymes 
protect normal cells under stress conditions, have the 
ability to inhibit damage to DNA, proteins, and lipids 
[11] and contribute to the generation of new tissue [12]. 
2. NRF2 AND CANCER 
The interest on the Nrf2 role in cancer has grown 
exponentially over the past eight years (Figure 2). Only 
in January 2018, we found 82 publications. If this 
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number was kept constant monthly for the rest of the 
year, we would reach about 1000 publications on this 
subject for 2018. 
In these years several studies confirmed that Nrf2 
has a cancer-protective activity via its cytoprotective 
functions, since it protects normal cells exposed to 
oxidative stress and xenobiotics, from DNA damage 
and destruction of the lipids, carbohydrates, and 
proteins [13]. It has been demonstrated that Nrf2-null 
mice also had decreased levels of phase II detoxifying 
enzymes and exhibited elevated sensitivity to the 
carcinogens and chemical toxicants [14]. On the 
contrary, recent studies have demonstrated that 
aberrant activation of NRF2, due to genetic and/or 
epigenetic mutations in tumor, contributes to the 
 
Figure 1: Schematic representation of Nrf2 function and regulation. Under normal condition, Keap1 binds Nrf2, causing its 
cytoplasmatic retention and mediating Nrf2 ubiquitination followed by proteasomal degradation; under oxidative stress, Nrf2 
dissociates from Keap1, translocates into the nucleus, binds to ARE, and transactivates phase II detoxifying enzymes and 
antioxidant genes. 
 
 
Figure 2: Number of publications per year on Nrf2 and Cancer. Number of publications per year obtained on PubMed with the 
following query: “(cancer OR Tumor) and Nrf2”. The last bar represents the number of publications relative to January 2018. 
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decreased therapeutic efficacy of anticancer drugs 
through biotransformation or extrusion during chemo-
therapy [9, 15]. The increase of Nrf2 expression can be 
related to the increased levels of reactive oxygen 
species (ROS), which has been observed in many 
types of cancer cells [16]. A moderate increase in ROS 
can promote cell proliferation and differentiation [17], 
whereas excessive amounts of ROS can cause 
oxidative damage to lipids, proteins and DNA [18]. An 
increase in ROS, associated with abnormal cancer cell 
growth, reflects a disruption of redox homeostasis and 
an increase of oxidative stress. Under persistent 
intrinsic oxidative stress, during cancer progression, 
many cancer cells become well-adapted to such stress 
and develop an enhanced, endogenous antioxidant 
capacity, which makes the malignant cells resistant to 
exogenous stress [19]. These intrinsically resistant 
cancer cells display high levels of Nrf2 expression 
which provides a growth advantage and diminishes the 
cytotoxic effects of anticancer agents [20]. 
Analogously, high expression of Nrf2 was also found in 
numerous cancer cell lines, which develop drug-
resistant phenotypes during chemotherapy [9, 15]. 
These resistant phenotypes can be induced to a great 
extent by anticancer drugs, such as such as alkylating 
agents and platinum compounds [21- 22]. Indeed, in 
chemo resistance induction, Nrf2 may act in different 
ways. Besides mediating stress-stimulated induction of 
antioxidant and detoxification genes, Nrf2 contributes 
to cancer cell resistance by up regulating the repair and 
degradation of damaged macromolecules, and by 
modulating intermediary metabolism [23]. Moreover, 
Nrf2 controls some genes belonging to the ABC (ATP-
binding cassette) super family of drug transporters. Bao 
et al. demonstrated that ABCF2, a cytosolic member of 
the ABC super family, involved in chemo resistance in 
clear cell ovarian cancer, contains ARE sequences in 
its promoter region, establishing ABCF2 as an NRF2 
target gene [24]. Canet and collaborators [25] identified 
a functional Nrf2 response element within the eighth 
intron of the ABCC3 gene, which may provide 
mechanistic insight to the Nrf2 induction of ABCC3, 
during antioxidant response stimuli. Finally, Ishikawa et 
al. demonstrated that Nrf2 interacts with the antioxidant 
responsive element (ARE) located in the promoter 
region of the human ABCG2 gene [26]. 
Finally, several studies identified cross-talk between 
Nrf2 and other signaling pathways involved in tumor 
progression (i.e. Yap, NF-kB Notch,) [22, 27-28], which 
provides extended functions of Nrf2 in regulating 
normal homeostasis as well as its contribution in the 
cancer dual role. 
3. NRF2 IN CHILDHOOD BRAIN TUMOR 
Central Nervous System (CNS) tumors are the 
second most common childhood cancers, after 
hematologic malignancies, representing 20 to 25% of 
all childhood cancers [29-31]. Although progress has 
been made in the treatment of pediatric tumors, 
significant mortality is still associated with malignant 
brain tumors. 
The universally adopted WHO classification of CNS 
tumors is based not only on histopathologic 
appearance, but also on well-established molecular 
parameters, such as the presence of mutated genes 
(i.e. isocitrate dehydrogenase- IDH, or WNT) [32]. The 
grading system, besides the classical morphological 
features (number of mitotic figures, the presence of 
necrosis, giant cells, vascular proliferation, 
hyperchromatic nuclei, the degree of pleomorphism), 
also includes these new molecular parameters [32]. 
Low-grade CNS cancers encompass WHO grade I and 
grade II tumors, whereas WHO grade III and IV are 
considered high-grade CNS malignancies [32]. 
The largest subgroup, in pediatric CNS tumor, is 
represented by gliomas. They account for 40-50% of all 
primary CNS tumors in children and they show an 
extremely broad range of clinical behavior. Most of the 
gliomas are diagnosed as low-grade and they are 
frequently indolent and do not undergo malignant 
transformation. Thus, they show excellent overall 
survival under current treatment strategies. However, 
some of these gliomas develop over a short period, 
progress rapidly and are therefore classified as WHO 
grade III or IV high-grade gliomas. Despite all 
therapeutic efforts, the mortality rate is very high, with 
the most aggressive forms being lethal within months 
[33]. 
The low-grade pilocytic astrocytoma represents the 
33.2% of gliomas, followed by other low-grade gliomas 
(27.1%), high-grade gliomas (i.e. anaplastic 
astrocytoma, and glioblastoma multiforme, GBM) 
(21.0%), and ependymal tumors (10.4%). The second 
most common group is represented by the embryonal 
tumors (15% of all childhood brain and CNS tumors). 
Most of these are medulloblastomas, followed by 
atypical teratoid / rhabdoid tumors (ATRT) (15.0%), 
and primitive neuroectodermal tumors (PNET) (14.9%) 
[29, 34]. 
14      Journal of Pediatric Oncology, 2017, Vol. 5 Giuseppina, et al. 
The dual role of Nrf2 has been elucidated in cells of 
nervous system similarly to that observed in several 
types of tissues. From one hand, Nrf2 has a 
neuroprotective action [35-36], from the other hand it 
can contribute to the cancer progression and 
chemoresistance in several CNS tumors [37-39]. 
Moreover, Tsai and collaborators observed that higher 
scores of Nrf2 immunostaining in primary CNS tumors 
are significantly correlated with more advanced World 
Health Organization (WHO) grades [40] (Figure 3). 
These authors analyzed 72 cases of astrocytic tumors 
of various WHO grades, and they found that the 
average expression scores of Nrf2 were 19.29 in 
pilocytic astrocytomas (WHO grade I), 75.98 in diffuse 
astrocytomas (WHO grade II), 114.00 in anaplastic 
astrocytomas (WHO grade III), 160.56 in glioblastomas 
multiforme (WHO grade IV), and 42.50 in gliosarcomas 
(WHO grade IV). Statistical analysis revealed a positive 
correlation between the Nrf2 expression score and 
WHO grade for astrocytic tumors. Similar results were 
obtained for oligodendroglial and ependymal tumors, 
where the average expression score of Nrf2 in 
anaplastic type (WHO grade III) was significantly higher 
than that in the corresponding lower WHO grade II. 
Among the neuroepithelial tumors, the WHO grade IV 
medulloblastoma showed the highest score of Nrf 
staining (170), similar to the values obtained for 
anaplastic ependymoma (171.11). More interestingly, 
patients whose glioma had higher Nrf2 expression 
tended to have lower overall survival (OS), although 
the association did not reach statistical significance 
[40]. 
The pro-tumoral role of Nrf2 has been extensively 
studied in glioblastoma multiforme (GMB), the most 
common and aggressive among all gliomas in adults, 
as recently reviewed [38]. Several reports have 
elucidated its contribution to chemo- and radio-
resistance, proliferation, invasion, migration, apoptosis, 
differentiation, and autophagy in GMB. Moreover, Nrf2 
modulation can influence the tumor microenvironment. 
For instance it has been demonstrated that Nrf2 
enhances angiogenesis; its activation induced up-
regulation of HO-1, and mediated the cellular adaptive 
survival response to a hypoxic conditions; moreover, it 
may regulate tumor immunosurveillance through 
regulation of the secretion of cytokines (IL-4, IL-5, and 
IL-13), affecting the function of immune cells and 
contributing to the immune escape [38]. For these 
reasons, several authors proposed Nrf2 as a promising 
therapeutic target in GMB. 
In contrast to the large literature on adult GMB, little 
is known about the role of Nrf2 in most of the common 
pediatric CNS tumors. For instance, few experimental 
papers are dealing with medulloblastoma and Nrf2. 
One of these confirmed that the expression levels of 
Nrf-2 and HO-1 in medulloblastoma young patients 
were significantly increased, compared with those 
observed in peritumoral control brain tissues, according 
to the studies on GMB [41]. A different approach was 
prosecuted by Koto and collaborators [42], who 
evaluated the anti-tumoral activity of two Nrf2 
activators, nifurtimox and Tetrathiomolybdate (TM), in 
two medulloblastoma cell lines, D283 and DAOY. The 
results obtained with a combined treatments were 
encouraging: these two drugs synergistically decreased 
medulloblastoma cell viability and induced cellular 
apoptosis. Consistent with the robust reactive oxygen 
species (ROS) production, these authors demonstrated 
 
Figure 3: Schematic representation of Nrf2 immunostaining in primary CNS tumors that significantly correlated with more 
advanced World Health Organization (WHO) grades, as demonstrated by Tsai and collaborators [38]. 
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that the drug combination caused the up-regulation of 
several target genes of the Nrf2 pathway. Although the 
encouraging results of this therapeutic approach, we 
believe that the activation of Nrf2 might be considered 
with caution. Indeed, as mentioned above, Nrf2 is 
involved in chemo-radio resistance, thereby its up-
regulation might promote tumor recurrence [9, 15]. At 
this regards, there is an interesting paper by Cong and 
collaborators [43], demonstrating that the standard care 
for newly diagnosed glioblastoma, including radio-
therapy plus concomitant and adjuvant temozolomide 
(TMZ, may improve the survival rated of patients, but it 
leads to the activation of Nrf2, which in turn might 
decrease chemo-radio sensitivity and promote 
glioblastoma recurrence. 
At the moment there are not specific studies on Nrf2 
in pediatric ependymoma. However, a very recent 
paper investigated, in adult ependymoma patients 
(median age 33 years), the immunohistochemical Nrf2 
expression, together with peroxiredoxins (Prxs), a very 
large and highly conserved family of antioxidant 
enzymes, able to reduce peroxides [44]. In particular, 
they studied 17 myxopapillary ependymomas (WHO 
grade I), 45 grade II ependymomas and 14 anaplastic 
ependymomas (WHO grade III) [45]. Strong nuclear 
and cytoplasmic expression of Nrf2 could be detected 
in these tumors and Prx I, a Nrf2 target, expression 
was significantly associated with cytoplasmic and 
nuclear Nrf2 expression. In contrast to what reported 
by Tsai and collaborators [40], neither nuclear Nrf2 nor 
Prxs expressions did not correlate with histological 
grade. 
Functional studies of Nrf2 on pilocytic astrocytoma, 
one of the most common pediatric CNS malignancies, 
are also missing. In consideration of its low expression 
with respect to higher WHO grade gliomas [40], it is 
very likely that it can have a marginal role in the 
progression of this tumor. 
Although the Nrf2 pathway in pediatric CNS tumors 
needs to be further investigated, a growing body of 
evidence suggests that it is frequently activated in 
many CNS tumors, and that its inhibition generally 
could sensitize tumor cells to pro-oxidant therapies, 
suggesting that Nrf2 inhibition is a promising strategy 
for cancer therapy. 
4. CLINICAL PERSPECTIVES 
Although consistent literature data highlight the 
possibility to use Nrf inhibitors to treat cancers [9, 46-
48], there are not ongoing clinical trials addressing this 
specific issue. One of the reasons is that although 
several anti-tumor agents that display activity as Nrf2 
inhibitor (i.e. ascorbic acid AA, all-trans-retinoic acid 
ATRA, metformin, glucocorticoids, brusatol, 
trigonelline, luteolin), they have poor specificity, low 
bioactivity, and toxicity, which represent major 
obstacles in developing clinical therapies. Moreover, 
the treatment of CNS tumors needs to consider an 
adjunctive crucial feature: the ability of the drug to 
cross the brain blood barrier (BBB). In this context, 
nanomedicine can play an important role by 
overcoming the above limitations [49]. Indeed, 
nanoparticles can penetrate and facilitate the drug 
delivery through the BBB, because in is possible to 
modulate their shape, size, hydrophobicity, coating, 
chemistry and surface charge. They can transport a 
variety of natural or synthetic compounds [50], and they 
represent an interesting therapeutical opportunity for 
the treatment of brain tumors [51]. 
Recently, nanoparticles have received attention for 
their use in RNA interference (RNAi) strategies, based 
on the highly specific and efficient silencing of a target 
gene. Indeed, these nanovectors can carry small RNA 
oligonucleotides, such as microRNA (miRNA) or small 
interfering RNA (siRNA) [52], and they have also been 
proposed for the treatment of glioblastoma [53]. Thus, 
in the absence of a specific Nrf2 inhibitor, the in vivo 
delivery of a specific siRNA targeting this gene, can 
represent an interesting strategy for treating CNS 
tumors. 
In conclusion, although little is known about the role 
of Nrf2 in most of the common pediatric CNS cancers, 
there is a strong suggestion for a clinical application of 
Nrf2 inhibitors in these type of tumors. Research 
program needs to fill the gaps and deepen the role of 
this gene in childhood brain tumor and to consider the 
development of new specific Nrf2 inhibitors able to 
cross the BBB. 
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